Drug Trial Radar · NCT00106288
Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia
Last checked: Nov 19, 2026Latest source record: Sep 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
637
Actual
Start
Jan 2003
Primary completion
Dec 2005
Study completion Dec 2005
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Mar 23, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy and safety of micafungin (FK463) versus liposomal amphotericin B (AmBisome) in treating neutropenic and non-neutropenic patients with confirmed invasive candidiasis or candidemia. Enrollment will include adult and pediatric patients.
Conditions
- Candidiasis
Interventions
MicafunginDrug
IV
Liposomal Amphotericin BDrug
IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator's assessment of overall treatment success. Success is defined as clinical (complete or partial) and mycological (eradication or presumed eradication) response at the End of Therapy.Time frame: 6 and 12 weeks post treatment
Locations
37 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Orange, California
Site not named
Denver, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Jacksonville, Florida
Site not named
Atlanta, Georgia
Site not named
Hinsdale, Illinois
Site not named
Maywood, Illinois
Site not named
Kansas City, Kansas
Site not named
Lexington, Kentucky
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Boston, Massachusetts
Site not named
Detroit, Michigan
Site not named
Minneapolis, Minnesota
Site not named
New York, New York
Site not named
New York, New York
Site not named
New York, New York
Site not named
Rochester, New York
Site not named
Valhalla, New York
Site not named
Durham, North Carolina
Site not named
Philadelphia, Pennsylvania
Site not named
Philadelphia, Pennsylvania
Site not named
Philadelphia, Pennsylvania
Site not named
Houston, Texas
Site not named
San Antonio, Texas
Site not named
Provo, Utah
Site not named
Calgary, Alberta, Canada
Site not named
Vancouver, British Columbia, Canada
Site not named
Winnipeg, Manitoba, Canada
Site not named
Halifax, Nova Scotia, Canada
Site not named
Hamilton, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Québec, Quebec, Canada
Site not named
Regina, Saskatchewan, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.